[go: up one dir, main page]

CL2008001296A1 - Uso de un antagonista del receptor y5 del npy para el tratamiento de un trastorno relacionado con el hipercortisolismo en un sujeto tal como el estres. - Google Patents

Uso de un antagonista del receptor y5 del npy para el tratamiento de un trastorno relacionado con el hipercortisolismo en un sujeto tal como el estres.

Info

Publication number
CL2008001296A1
CL2008001296A1 CL2008001296A CL2008001296A CL2008001296A1 CL 2008001296 A1 CL2008001296 A1 CL 2008001296A1 CL 2008001296 A CL2008001296 A CL 2008001296A CL 2008001296 A CL2008001296 A CL 2008001296A CL 2008001296 A1 CL2008001296 A1 CL 2008001296A1
Authority
CL
Chile
Prior art keywords
hypercortisolism
npy
stress
subject
treatment
Prior art date
Application number
CL2008001296A
Other languages
English (en)
Inventor
Peter Hongaard Andersen
Mary Walker
Irina Antonijevic
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CL2008001296A1 publication Critical patent/CL2008001296A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/301—Anxiety or phobic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/303—Eating disorders, e.g. anorexia, bulimia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Uso de un antagonista del receptor y5 del npy para el tratamiento de un trastorno relacionado con el hipercortisolismo en un sujeto, tal como, el estrés.
CL2008001296A 2007-05-04 2008-05-05 Uso de un antagonista del receptor y5 del npy para el tratamiento de un trastorno relacionado con el hipercortisolismo en un sujeto tal como el estres. CL2008001296A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91623207P 2007-05-04 2007-05-04
US95042107P 2007-07-18 2007-07-18

Publications (1)

Publication Number Publication Date
CL2008001296A1 true CL2008001296A1 (es) 2009-03-06

Family

ID=39943883

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008001296A CL2008001296A1 (es) 2007-05-04 2008-05-05 Uso de un antagonista del receptor y5 del npy para el tratamiento de un trastorno relacionado con el hipercortisolismo en un sujeto tal como el estres.

Country Status (3)

Country Link
AR (1) AR066334A1 (es)
CL (1) CL2008001296A1 (es)
WO (1) WO2008137270A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1205789A1 (en) * 2012-03-13 2015-12-24 Abbvie Inc. Method for selecting or identifying a subject for v1b antagonist therapy
MX364295B (es) * 2012-11-07 2019-04-22 Karus Therapeutics Ltd Inhibidores de histona desacetilasa novedosos y su uso en terapia.
SMT201800501T1 (it) 2013-05-10 2018-11-09 Karus Therapeutics Ltd Nuovi inibitori di istone deacetilasi
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602024A (en) * 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
CN1556709A (zh) * 2001-03-23 2004-12-22 �Ƹ��� 使用糖皮质激素受体特效拮抗剂治疗压力症的方法
EP1628660A4 (en) * 2003-06-02 2010-06-02 Samaritan Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR MODULATING THE CORTISOL SERUM MIRRORS

Also Published As

Publication number Publication date
WO2008137270A1 (en) 2008-11-13
AR066334A1 (es) 2009-08-12

Similar Documents

Publication Publication Date Title
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
CL2009000545A1 (es) Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
GB201017345D0 (en) Receptor antagonists
CL2012003053A1 (es) Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad.
EA201171367A1 (ru) Винилиндазолильные соединения
CL2013002001A1 (es) Uso de un agonista del receptor tipo toll para el tratamiento del cancer.
MX2013015168A (es) Co-agonista del receptor de glucagon/glp-1.
PH12013502671A1 (en) Glucagon/glp-1 receptor co-agonists
SMT201400019B (it) Antagonisti del recettore di CGRP
IT1394472B1 (it) Tavolo per riunioni.
CL2015002616A1 (es) 7-azabiciclos sustituidos y su uso como modulares del receptor de orexina.
UY34200A (es) 3-(fluorovinil)pirazoles y su uso
UY34730A (es) Formulaciones farmacéuticas que comprenden antagonistas de ccr3
CL2009000532A1 (es) Compuestos derivados de piridin-2-ilo; agonista del receptor s1p1/edg1; composición farmacéutica que los comprende; uso en trastornos asociados con el sitema inmunitario.
CL2013002823A1 (es) Compuestos derivados de morfolinotieno[3,2-d]pirimidin-6-il-metil-(metilamino)-n-hidroxipirimidina-5-carboxamida, inhibidores de la pi3 quinasa; composicion farmaceutica que los comprende; su uso en el tratamiento de un trastorno de proliferacion celular tal como el cancer.
CL2008000091A1 (es) Compuestos derivados de piridina, inhibidores del receptor p2y12; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento del trastorno de agregacion plaquetaria.
CL2008001296A1 (es) Uso de un antagonista del receptor y5 del npy para el tratamiento de un trastorno relacionado con el hipercortisolismo en un sujeto tal como el estres.
UY34677A (es) Imidazopiridazinas sustituidas
JP2012513655A5 (es)
BRPI1009090A2 (pt) composto, pró-droga, medicamento, métodos, e, uso do composto
CL2008000092A1 (es) Compuestos derivados de 3-cianopiridina, inhibidores del receptor p2y12; composicion farmaceutica que comprende a dichos compustos; y su uso en el tratamiento del transtorno de la agregacion plaquetaria.
CY1116283T1 (el) Δοσολογια μοναδας apadenoson
IT1399581B1 (it) Dispositivo per la protezione di parti del corpo di un individuo, in particolare per la protezione della schiena.
PA8849101A1 (es) Procedimiento de preparación del hemifumarato de eplivanserina
IT201700099945A1 (it) Struttura in fibre libere per imbottiture.